Shares of Zoetis ZTS have plunged 24.8% year to date, amid mounting safety concerns surrounding its monoclonal antibody osteoarthritis (OA)pain therapies — Librela for dogs and Solensia for cats. With ...

Revenue: $2.4 billion in Q3, 1% growth on a reported basis, 4% organic operational growth. Adjusted Net Income: $754 million, 5% growth on a reported basis, 9% organic operational growth. Companion ...

INDIANAPOLIS, Ind., Oct. 27, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced label expansions for two of its leading canine prescription parasiticides, Credelio ...

ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela ...

Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has assisted thousands of clients over a more than two-decade career. She is the CEO of ...

Welcome to the Second Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation ...

Zoetis Inc. reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $1.76, compared to the forecasted $1.62. The company’s revenue also ...

Zoetis Inc. reported a strong financial performance for Q1 2025, surpassing analysts’ expectations with earnings per share (EPS) of $1.48 against a forecast of $1.41. The company also exceeded revenue ...

What Are Simparica Products for Fleas, Ticks, and Heartworms? The Simparica line of products (manufactured by Zoetis) includes chewable tablets (products that are given by mouth) for the prevention, ...

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, ...